EV / EBITDA společnosti Suda Pharmaceuticals Ltd
Jaká je hodnota metriky EV / EBITDA společnosti Suda Pharmaceuticals Ltd?
Hodnota metriky EV / EBITDA společnosti Suda Pharmaceuticals Ltd je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na ASX ve srovnání se společností Suda Pharmaceuticals Ltd
Čemu se věnuje společnost Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Firmy s metrikou ev / ebitda podobnou společnosti Suda Pharmaceuticals Ltd
- Hodnota metriky EV / EBITDA společnosti C4X Discovery Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Pacgen Life Science je N/A
- Hodnota metriky EV / EBITDA společnosti Panther Metals Plc je N/A
- Hodnota metriky EV / EBITDA společnosti InnovaDerma Plc je N/A
- Hodnota metriky EV / EBITDA společnosti CryptoStar je N/A
- Hodnota metriky EV / EBITDA společnosti CHAR Technologies je N/A
- Hodnota metriky EV / EBITDA společnosti Suda Pharmaceuticals Ltd je N/A
- Hodnota metriky EV / EBITDA společnosti Dixie Gold je N/A
- Hodnota metriky EV / EBITDA společnosti Novacyt S.A je N/A
- Hodnota metriky EV / EBITDA společnosti Bald Eagle Gold je N/A
- Hodnota metriky EV / EBITDA společnosti Pier 1 Imports Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Element 29 Resources Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Standard BioTools Inc je N/A